Navigation Links
Choice Of Treatment Increases Risk Of Death In Kidney Disease

People who are suffering from kidney diseases may have increased risk of death if they choose the wrong dialysis option.

Researchers from Johns Hopkins University School of Medicine have found that in people// with end-stage kidney disease (ESRD), choosing peritoneal dialysis over hemodialysis increases their risk of dying by 50 percent.

The findings, to be published in the journal Annals of Internal Medicine online Aug. 1, are from one of the first comprehensive, large-scale, follow-up comparison studies in the debate about which kind of dialysis is better.

To find out, the study, called the Choices for Healthy Outcomes in Caring for ESRD, or CHOICE for short, followed 1,041 newly diagnosed patients from 81 dialysis clinics across the United States and monitored their health, mainly through reviews of patient charts and medical records, for eight years while they underwent dialysis treatment. The study participants, men and women between 18 and 96 years old, chose the method of dialysis: 274 selected peritoneal dialysis and 767 selected hemodialysis.

Initial results showed that during the first year of treatment, patients choosing peritoneal dialysis were doing as well as patients on hemodialysis. Death rates early in the study were 21 percent and 24 percent, respectively.

When these differences were taken into account, the researchers discovered that while healthy patients did well on either form of dialysis, hemodialysis was of greater benefit for those patients with coexisting illnesses, such as cardiovascular disease. The risk of death among 135 patients with cardiovascular disease who were using peritoneal dialysis was nearly twice that of 459 similar patients on hemodialysis. After one year of dialysis treatment, the risk of death for patients who started on peritoneal dialysis was greater than the risk of death for patients who started on hemodialysis.

Source: Newswise

Medin
'"/>




Page: 1 2

Related medicine news :

1. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
2. Hypertension Drug of Choice for African Americans
3. Patient Choice Cesarean Section on The Rise
4. Athletes Are More Prone To Environmental Pollutants Due To Choice Of Diet
5. Learning About Healthy Diet Choices Begins At Schools
6. Voice Choice: Woo Men, Strike a Deep Chord
7. Terminally Ill: End Of Life Choices
8. Allergy Alarm: Sams Choice Milk Chocolate Turns Bitter with Undisclosed Nuts
9. Wider Addictive Choices – Now, Tanned Addicts
10. Big Brands Ensure Lasting Influences In Dietary Choices.
11. Decision-Making Enabled By Neurons: Value Assigned To Available Choices.
Post Your Comments:
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2
...hool districts receiving grants to ...fourth consecutive year, Blue,Cross Blue Shield of... are,helping schools across the state launch activ...ssential activities to promote physical activity, ...
...university Karolinska Institutet have shown that h...val of the uterus greatly increases the risk of u...om a nationwide study, are presented in The Lancet...in order to improve life quality for the patients....
...to be a multi-stage, multi-mechanism process by an...the role of Helicobacter pylori (H pylori) in the ...rticle to be published on November 7 in the World ... structures necessary for cell differentiation, ti...
...cal,Systems, (NYSE: VAR ) has been ranked first i...he ServiceTrak(TM) 2007 survey report on radiation...esearch company that,analyzes service trends in va...out of 34 of the service attributes covered,by thi...
...lack Engineer and Information, Technology Magazin...ity, ABBOTT PARK, Ill., Oct. 26 Abbott (NYSE: A...for diversity in two publications.,Abbott was name...iversity in the magazine. In addition, Abbott was,...
...anization dedicated to autism spectrum diso...IEGO, Oct. 26 The San Diego County,Chapter of the...TACA and,the Autism Society of America, are offeri... "Offers of support for fire victims from both th...
Other Medicine News:Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 2Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 3Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 4Health News:Blue Cross Blue Shield of Michigan and Schools Partner to Get Kids More Active 5Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals 2Health News:Abbott Again Honored as a Leader in Diversity 2Health News:Abbott Again Honored as a Leader in Diversity 3Health News:ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Scientists find that individuals in vegetative states can learn 9986 1Scientists find that individuals in vegetative states can learn 9986 2New Chemo Regimen May Benefit Ovarian Cancer Patients 57711 1New Chemo Regimen May Benefit Ovarian Cancer Patients 57711 2U of C alumnus finds high numbers of heat loving bacteria in cold Arctic Ocean 9984 1U of C alumnus finds high numbers of heat loving bacteria in cold Arctic Ocean 9984 2
... inhibitor, and R7128, nucleoside polymerase inhib...load in patients with hepatitis C - , , NUTLEY, ... 25 Roche, InterMune, Inc. (Nasdaq: ITMN ) and ...irst results from their innovative, interferon-fre...tion therapy for the treatment of patients chronic...
...ion milestone payment to Pharmasset , , PRINCETON... ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHH...n dosed in a Phase IIb study of R7128, the nucleos...ent for the treatment of chronic hepatitis C (HCV)... treatment of R7128 in combination with Roche,s PE...
Other Medicine Technology:Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: